"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

The Risk of Second Malignancies after Seed Migration in Prostate Cancer Patients Treated With I-125 Free Seeds Brachytherapy


Abstract

Purpose/Objective(s)

To evaluate the risk of second malignancies after seed migration in prostate cancer patients treated with I-125 free seeds brachytherapy.

Materials/Methods

Data from 2067 prostate cancer patients treated with I-125 free seeds brachytherapy in three Canadian centers were analyzed. Kaplan-Meier method was used to estimate the 5- and 7-year biochemical relapse-free and overall survival between patients who experienced or not seed migration.

Results

Mean age and Median follow-up was 64 years and 44 (range 1-147) months, respectively. Seed migration occurred in 365 of 2067 patients (17.7%). The 5-, 7-year biochemical relapse-free and overall survival for the entire cohort was 96%, 91.7% and 95.9%, 93.7%, respectively. Second malignancies occurred in 4 of 365 patients (1.1%) and 21 of 1702 patients (1.2%) in patients with or without seed migration, respectively (p=0.827). Lung cancer represented the most frequent second malignancy observed and occurred in 6 patients, all in the no seed migration group. The other second malignancies observed in the no seed migration group included: larynx (3 patients), colon (2 patients), esophagus (2), pancreatic (2), renal, myeloma, glioblastoma, non-Hodgkin’s lymphoma (1) and 2 unknown. In the seed migration group, the second malignancies observed were chronic myeloid leukemia (1), colo-rectal cancer (2) and nasopharynx (1).

Conclusion

These results do not support an increased risk of second malignancies, particularly lung cancer with seed migration after I-125 free seeds brachytherapy for prostate cancer patients. Due to the low rate of second malignancies observed in this cohort, further studies with longer follow-up are required to better correlate seed migration and second malignancies.

Poster
non-peer-reviewed

The Risk of Second Malignancies after Seed Migration in Prostate Cancer Patients Treated With I-125 Free Seeds Brachytherapy


Author Information

Eric Vigneault Corresponding Author

Radiation-Oncology, Hotel Dieu de Quebc

Kevin Martell

Radiation Oncology, University of Calgary, Calgary, Ab, Canada

Daniel Taussky

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Siraj Hussein

Radiation Oncology, Cross Cancer Center, Calgary

Guila Delouya

Department of Radiation Oncology, Centre hospitalier de l’Université de Montréal (CHUM)

Khaly Mbodji

Centre de recherche du CHU de Québec, CHU de Québec – Université Laval

Julie Piotte

Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Sindy Magnan

Medical Physics, Université Laval

Philippe Despres

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Marie C. Lavallee

Radiation Oncology, CHU de Québec – Université Laval

Sylviane Aubin

Radiation Oncology, CHU De Québec

Luc Beaulieu

Medical Physics, Université Laval

William Foster

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Andre-Guy Martin

Radiation Oncology, Centre Hospitalier Universitaire de Québec - L'Hôtel-Dieu de Québec, Québec, QC


PDF Print Share
  • Author Information
    Eric Vigneault

    Radiation-Oncology, Hotel Dieu de Quebc

    Kevin Martell

    Radiation Oncology, University of Calgary, Calgary, Ab, Canada

    Daniel Taussky

    Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

    Siraj Hussein

    Radiation Oncology, Cross Cancer Center, Calgary

    Guila Delouya

    Department of Radiation Oncology, Centre hospitalier de l’Université de Montréal (CHUM)

    Khaly Mbodji

    Centre de recherche du CHU de Québec, CHU de Québec – Université Laval

    Julie Piotte

    Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

    Sindy Magnan

    Medical Physics, Université Laval

    Philippe Despres

    Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

    Marie C. Lavallee

    Radiation Oncology, CHU de Québec – Université Laval

    Sylviane Aubin

    Radiation Oncology, CHU De Québec

    Luc Beaulieu

    Medical Physics, Université Laval

    William Foster

    Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

    Andre-Guy Martin

    Radiation Oncology, Centre Hospitalier Universitaire de Québec - L'Hôtel-Dieu de Québec, Québec, QC

    Poster Information
    Meeting

    CARO 2017 Annual Scientific Meeting September 13, 2017 - September 16, 2017

    Publication history

    Received by Cureus: September 06, 2017
    Published: September 13, 2017

    License

    This is an open access poster distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Purpose/Objective(s)

To evaluate the risk of second malignancies after seed migration in prostate cancer patients treated with I-125 free seeds brachytherapy.

Materials/Methods

Data from 2067 prostate cancer patients treated with I-125 free seeds brachytherapy in three Canadian centers were analyzed. Kaplan-Meier method was used to estimate the 5- and 7-year biochemical relapse-free and overall survival between patients who experienced or not seed migration.

Results

Mean age and Median follow-up was 64 years and 44 (range 1-147) months, respectively. Seed migration occurred in 365 of 2067 patients (17.7%). The 5-, 7-year biochemical relapse-free and overall survival for the entire cohort was 96%, 91.7% and 95.9%, 93.7%, respectively. Second malignancies occurred in 4 of 365 patients (1.1%) and 21 of 1702 patients (1.2%) in patients with or without seed migration, respectively (p=0.827). Lung cancer represented the most frequent second malignancy observed and occurred in 6 patients, all in the no seed migration group. The other second malignancies observed in the no seed migration group included: larynx (3 patients), colon (2 patients), esophagus (2), pancreatic (2), renal, myeloma, glioblastoma, non-Hodgkin’s lymphoma (1) and 2 unknown. In the seed migration group, the second malignancies observed were chronic myeloid leukemia (1), colo-rectal cancer (2) and nasopharynx (1).

Conclusion

These results do not support an increased risk of second malignancies, particularly lung cancer with seed migration after I-125 free seeds brachytherapy for prostate cancer patients. Due to the low rate of second malignancies observed in this cohort, further studies with longer follow-up are required to better correlate seed migration and second malignancies.

Eric Vigneault

Radiation-Oncology, Hotel Dieu de Quebc

For correspondence:
eric.vigneault@mail.chuq.qc.ca

Kevin Martell

Radiation Oncology, University of Calgary, Calgary, Ab, Canada

Daniel Taussky, None

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Siraj Hussein

Radiation Oncology, Cross Cancer Center, Calgary

Guila Delouya

Department of Radiation Oncology, Centre hospitalier de l’Université de Montréal (CHUM)

Khaly Mbodji

Centre de recherche du CHU de Québec, CHU de Québec – Université Laval

Julie Piotte

Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Sindy Magnan

Medical Physics, Université Laval

Philippe Despres

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Marie C. Lavallee

Radiation Oncology, CHU de Québec – Université Laval

Sylviane Aubin

Radiation Oncology, CHU De Québec

Luc Beaulieu

Medical Physics, Université Laval

William Foster

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Andre-Guy Martin

Radiation Oncology, Centre Hospitalier Universitaire de Québec - L'Hôtel-Dieu de Québec, Québec, QC

Eric Vigneault

Radiation-Oncology, Hotel Dieu de Quebc

For correspondence:
eric.vigneault@mail.chuq.qc.ca

Kevin Martell

Radiation Oncology, University of Calgary, Calgary, Ab, Canada

Daniel Taussky, None

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Siraj Hussein

Radiation Oncology, Cross Cancer Center, Calgary

Guila Delouya

Department of Radiation Oncology, Centre hospitalier de l’Université de Montréal (CHUM)

Khaly Mbodji

Centre de recherche du CHU de Québec, CHU de Québec – Université Laval

Julie Piotte

Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Sindy Magnan

Medical Physics, Université Laval

Philippe Despres

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Marie C. Lavallee

Radiation Oncology, CHU de Québec – Université Laval

Sylviane Aubin

Radiation Oncology, CHU De Québec

Luc Beaulieu

Medical Physics, Université Laval

William Foster

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Andre-Guy Martin

Radiation Oncology, Centre Hospitalier Universitaire de Québec - L'Hôtel-Dieu de Québec, Québec, QC

Eric Vigneault

Radiation-Oncology, Hotel Dieu de Quebc

For correspondence:
eric.vigneault@mail.chuq.qc.ca

Kevin Martell

Radiation Oncology, University of Calgary, Calgary, Ab, Canada

Daniel Taussky, None

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Siraj Hussein

Radiation Oncology, Cross Cancer Center, Calgary

Guila Delouya

Department of Radiation Oncology, Centre hospitalier de l’Université de Montréal (CHUM)

Khaly Mbodji

Centre de recherche du CHU de Québec, CHU de Québec – Université Laval

Julie Piotte

Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Sindy Magnan

Medical Physics, Université Laval

Philippe Despres

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Marie C. Lavallee

Radiation Oncology, CHU de Québec – Université Laval

Sylviane Aubin

Radiation Oncology, CHU De Québec

Luc Beaulieu

Medical Physics, Université Laval

William Foster

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Andre-Guy Martin

Radiation Oncology, Centre Hospitalier Universitaire de Québec - L'Hôtel-Dieu de Québec, Québec, QC

Converted fe1d2eb0933311e7bc27994b300f7040 postercaro2017migration